Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Bad
|
New words:
ABP, adjacent, affectPegIntron, al, Alaska, alfa, analog, andBridion, andClaritin, andDulera, andDuleraInhalation, andParacox, andProQuad, andRebetol, andSimponi, andSinemet, andTredaptive, andVytorincould, andZetiaand, andZioptan, andZocor, antibacterial, antipsychotic, approvedCosopt, approvedJanumet, approvedJuvisync, approvedSylatron, approvedZioptan, approvedZoely, AQ, art, asDulera, asSaflutan, asSingulairand, asSingularand, asTemodal, asZoely, atherothrombotic, AzaSite, Bauer, Becton, begun, biennial, BioManufacturing, bleeding, block, blockade, Bordetella, Brown, byNuvaRing, CanadianVioxxlitigation, canal, career, Carter, cessation, childbirth, clot, collar, combinesJanuvia, complementary, concede, Congressional, content, cough, David, deadline, debated, deluca, deployed, deprioritized, Dickinson, die, digit, dismissedRose, dissemination, Dodge, drainage, Elkhorn, ERP, exact, exceeded, Femina, femur, finasteride, FlowsConsolidated, forBridion, forDulera, forElonva, forMachinery, forPropecia, forRemicade, forSycrest, Fort, forZoely, fromRemicade, Fujifilm, Gardasil, Garrett, Georgia, guilty, HCI, hematological, hematopoietic, hexavalent, higherCosopt, HyzaarandTemodar, Idaho, inAOCIin, inAOCIuntil, inCarballo, includeGardasil, includingSingulair, incomefrom, inCozaarandHyzaar, inDr, inErnst, infliximab, infusion, inJanuvia, inPedrojetti, inRose, inSecrest, Inspire, interfere, involvingPropecia, Iowa, irrigation, ITC, JJMCP, Joel, kg, knowledge, Lastly, launchCosopt, lengthened, Lenovo, Liechtenstein, lipoprotein, lymphadenectomy, macro, manufactureNuvaRing, marketRemicade, maternal, Maxaltin, medicationJanuvia, medicationZocor, microscopic, Mine, misbranding, misdemeanor, Mississippi, monophasic, MRL, MRSA, Mylanta, Mylicon, narrowed, neuromuscular, NJ, nodal, nomegestrol, ofAOCI, ofClostridium, ofClostridiumdifficile, ofCoppertone, ofCosopt, ofCosoptandTrusopt, ofCozaarandHyzaar, ofEmendincreased, offshore, ofIntegrilin, ofNoxafil, ofPegIntron, ofProQuadwere, ofRemicade, ofRotaTeq, ofVaqta, ofVioxxseeking, ofZoely, ONJ, orOCI, orphan, orVytorin, OTCPepcid, OTCtreatment, pancreatic, peginterferon, Perk, PF, Pisano, plea, plead, Pneumovaxand, polio, posture, preexisting, pregnancy, premium, pretrial, productNuvaRing, productsCosoptandTrusopt, productsZetia, reopen, rescheduled, resection, resubmission, REVEAL, Riverside, rodent, Ronald, Russia, secondFosamax, severalVioxx, sexual, Simponi, subsidized, sudden, summer, surface, suspended, suvorexant, TE, testimony, thatNuvaRing, thatVioxx, theCain, theCarrie, theErnst, theFlemingscase, thePepcid, theSessner, theTemodar, TheWard, theZioptan, toAOCI, toIntegrilinandAvelox, toJanuvia, toPegIntron, toRemicade, Torrent, toSinemet, toSycrest, transplant, tumor, twenty, untreated, vaniprevir, vial, Virginia, VytorinandZetia, wasRaber, weighing, whooping, Wisconsin, withGardasil, withinResearch, withPegIntron, withSessner, woman, ZetiaandNasonex, zone, Zuellig
Removed:
aggressive, agreeable, anesthesia, Argentina, award, BSE, cease, choose, compensatory, confirmed, Crohn, deductible, delivered, Deputy, enrollment, entry, expectation, femoral, fiscal, gained, goal, GP, half, Head, improved, indefinite, independently, inRule, instituted, intervention, invalid, joining, kohan, leadership, mandate, mutual, noncontrolling, oversee, pegylated, pertained, platelet, prevail, procedural, qualifying, raul, refer, repurchase, repurchased, reverse, routine, SCH, science, Scotland, Secretary, statutorily, steering, streamlining, sum, transparent, trust, unlawful, unpaid, unstable, validity, violated, vote, worked
Filing tables
Filing exhibits
- 10-K Annual report
- 10.20 Stock Option Terms for 2012 Quarterly and Annual Non-qualified Option Grants
- 10.21 Restricted Stock Unit Terms for 2012 Quarterly and Annual Grants
- 10.28 Merck & Co., Inc. U.S. Separation Benefits Plan
- 10.29 Important Information on the Separation Program
- 10.30 Important Information on the Separation Program
- 10.31 Important Information on the Separation Program
- 10.32 Important Information on the Separation Program
- 10.33 Important Information on the Separation Program
- 10.34 Important Information on the Separation Program
- 10.35 Important Information on the Separation Program
- 12 Computation of Ratios of Earnings to Fixed Charges
- 21 Subsidiaries of Merck & Co., Inc.
- 24.1 Power of Attorney
- 24.2 Certified Resolution of Board of Directors
- 31.1 Rule 13A-14(A)/15D-14(A) Certification of Chief Executive Officer
- 31.2 Rule 13A-14(A)/15D-14(A) Certification of Chief Financial Officer
- 32.1 Section 1350 Certification of Chief Executive Officer
- 32.2 Section 1350 Certification of Chief Financial Officer
- CORRESP Corresp
Related press release
MRK similar filings
Filing view
External links
MERCK & CO., INC.
ONE MERCK DRIVE
P.O. BOX 100
WHITEHOUSE STATION, NJ 08889-0100
February 28, 2012
Securities and Exchange Commission
100 F Street
Washington, DC 20549
Re: | Merck & Co., Inc. | |
Form 10-K Annual Report for the | ||
Fiscal year Ended December 31, 2011 | ||
File No. 1-6571 |
Ladies and Gentlemen:
On behalf of Merck & Co., Inc., pursuant to Regulation S-T, submitted herewith for filing is the Company’s Annual Report on Form 10-K, including the exhibits thereto.
The financial statements do not reflect any changes from the preceding year in any accounting principles or practices, or in the method of applying any such accounting principles or practices.
Very truly yours,
/s/Katie E. Fedosz |
Katie E. Fedosz |
Senior Assistant Secretary |